Kerr David, Rajpura Jigar Ramesh, Namvar Tarlan
Center for Health Systems Research, Sutter Health, Santa Barbara, CA, USA.
Department of US Health Economic and Outcomes Research - Rare Disease Portfolio, Novo Nordisk Inc, Plainsboro, NJ, USA.
Patient Prefer Adherence. 2024 Feb 14;18:411-424. doi: 10.2147/PPA.S436540. eCollection 2024.
The global burden of disease of type 2 diabetes (T2D) is significant, and insulin currently plays a central role in T2D management. This study sought to assess the preferences of patients with T2D and healthcare providers (HCPs) involved in T2D care regarding a hypothetical once-weekly basal insulin in comparison to current basal insulin options.
In a survey-based study in the United States that included a discrete choice experiment (DCE), patients with T2D (insulin naïve and current insulin users) and providers who treat individuals with T2D were asked to evaluate current basal insulins and identify attributes of importance regarding a hypothetical once-weekly basal insulin. A regression analysis was conducted to identify drivers of preference by relevant demographics, attitudes, and behaviors.
Most respondents (91% of patients with T2D and 89% of HCPs in the base case scenario) would choose a once-weekly basal insulin product over another type of basal insulin. Both patients with T2D and HCPs rated insulin type and delivery method to be attributes of highest importance in the discrete choice exercise. Current basal insulin users ("insulin experienced") reported higher levels of confidence that a once-weekly insulin would help them to achieve their desired blood sugar levels compared to their current basal insulin (5.7 vs 5.2 on a 7-point Likert scale). Most insulin-experienced respondents (88%) were likely to inquire about once-weekly basal insulin, and most HCPs (85%) indicated willingness to educate patients on management of their T2D using a once-weekly basal insulin.
Discussing preferences for T2D medication management is important for patients and HCPs to ensure treatments are offered for patients based on their preferences. This study showed that patient and provider preferences are similar towards a once-weekly basal insulin over current basal insulin preparations.
2型糖尿病(T2D)的全球疾病负担颇为重大,胰岛素目前在T2D管理中发挥着核心作用。本研究旨在评估T2D患者以及参与T2D护理的医疗服务提供者(HCPs)对于一种假设的每周一次基础胰岛素相较于当前基础胰岛素选择的偏好。
在美国开展的一项基于调查的研究,其中包括离散选择实验(DCE),研究人员要求T2D患者(未使用过胰岛素者和当前胰岛素使用者)以及治疗T2D患者的医疗服务提供者评估当前的基础胰岛素,并确定关于一种假设的每周一次基础胰岛素的重要属性。进行回归分析以确定相关人口统计学、态度和行为对偏好的驱动因素。
在基础病例情景中,大多数受访者(91%的T2D患者和89%的HCPs)会选择每周一次基础胰岛素产品而非另一种基础胰岛素。T2D患者和HCPs均将胰岛素类型和给药方式评为离散选择练习中最重要的属性。与当前基础胰岛素相比,当前基础胰岛素使用者(“有胰岛素使用经验者”)报告称对每周一次胰岛素有助于他们达到理想血糖水平的信心更高(在7分李克特量表上为5.7分对5.2分)。大多数有胰岛素使用经验的受访者(88%)可能会询问每周一次基础胰岛素,大多数HCPs(85%)表示愿意就使用每周一次基础胰岛素管理T2D对患者进行教育。
讨论T2D药物管理的偏好对于患者和HCPs很重要,以确保根据患者偏好为其提供治疗。本研究表明,相较于当前基础胰岛素制剂,患者和医疗服务提供者对每周一次基础胰岛素的偏好相似。